Castle Creek Biosciences, Inc

Castle Creek Biosciences, Inc., located in Exton, PA, is dedicated to developing innovative gene therapies aimed at improving the lives of patients suffering from genetic diseases, particularly dystrophic epidermolysis bullosa (DEB). The company is currently conducting a registrational Phase 3 trial to provide relief for those affected by this devastating condition.

Under the leadership of President and CEO Matthew Gantz, Castle Creek is committed to creating optimal treatments through its proprietary autologous fibroblast technology. The organization strives to build a leading cell and gene therapy company that addresses the needs of patients and their families.

Generated from the website